Qianjin Pharmaceutical announced on July 20 that its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for baclofen tablets approved and issued by the State Drug Administration. Baclofen tablets are suitable for severe but reversible muscle spasms caused by multiple sclerosis, and may have a certain curative effect on spasms caused by infectious, degenerative, traumatic, tumors, or spinal cord diseases of unknown cause.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.